Table 2.
Biomarker scores of the liver graft biopsies obtained at the first follow-up in the whole group (n=51) and in those with (n=20) and without (n=31) simultaneous fibrosis. Data are presented as number of patients in each group (percentage). Some of the biopsies were insufficient for all 6 stainings or for a reliable evaluation of the 3 histological areas. For this reason, the number of scored samples shows some variation between the different stainings.
| All patients (n=51) | Patients without fibrosis (n=31) | Patients with fibrosis (n=20) | p-value* | |
|---|---|---|---|---|
| α-SMA | ||||
| Portal | 0.000 | |||
| 0 | 29 (63) | 24 (86) | 5 (28) | |
| 1 | 12 (26) | 4 (13) | 8 (44) | |
| 2 | 5 (11) | 0 (0) | 5 (28) | |
| Lobular | 0.000 | |||
| 0 | 25 (54) | 21 (68) | 4 (22) | |
| 1 | 10 (22) | 6 (19) | 4 (22) | |
| 2 | 11 (24) | 1 (3) | 10 (56) | |
| Central | 0.027 | |||
| 0 | 36 (78) | 25 (89) | 11 (61) | |
| 1 | 7 (15) | 2 (7) | 5 (28) | |
| 2 | 3 (7) | 1 (4) | 2 (11) | |
| Type I collagen | ||||
| Portal | 0.001 | |||
| 0 | 31 (63) | 24 (80) | 7 (37) | |
| 1 | 13 (27) | 6 (20) | 7 (37) | |
| 2 | 5 (10) | 0 (0) | 5 (26) | |
| Lobular | 0.006 | |||
| 0 | 41 (82) | 29 (94) | 12 (63) | |
| 1 | 7 (14) | 2 (7) | 5 (26) | |
| 2 | 2 (4) | 0 (0) | 2 (11) | |
| Central | 0.002 | |||
| 0 | 38 (79) | 28 (93) | 10 (56) | |
| 1 | 7 (15) | 2 (7) | 5 (28) | |
| 2 | 3 (6) | 0 (0) | 3 (17) | |
| Decorin | ||||
| Portal | 0.117 | |||
| 0 | 26 (63) | 17 (71) | 9 (53) | |
| 1 | 11 (27) | 7 (29) | 4 (24) | |
| 2 | 4 (10) | 0 (0) | 4 (24) | |
| Lobular | 0.010 | |||
| 0 | 28 (68) | 20 (83) | 8 (47) | |
| 1 | 10 (24) | 4 (17) | 6 (35) | |
| 2 | 3 (7) | 0 (0) | 3 (18) | |
| Central | 0.055 | |||
| 0 | 33 (83) | 22 (92) | 11 (69) | |
| 1 | 5 (13) | 2 (8) | 3 (19) | |
| 2 | 2 (5) | 0 (0) | 2 (13) | |
| Vimentin | ||||
| Portal | 0.001 | |||
| 0 | 17 (42) | 15 (63) | 2 (12) | |
| 1 | 18 (44) | 8 (33) | 10 (59) | |
| 2 | 6 (12) | 1 (4) | 5 (29) | |
| Lobular | 0.010 | |||
| 0 | 23 (56) | 17 (71) | 6 (35) | |
| 1 | 14 (34) | 7 (29) | 7 (41) | |
| 2 | 4 (10) | 0 (0) | 4 (24) | |
| Central | 0.769 | |||
| 0 | 38 (93) | 22 (92) | 16 (94) | |
| 1 | 0 (0) | 0 (0) | 0 (0) | |
| 2 | 3 (7) | 2 (8) | 1 (6) | |
| PSGL-1 | ||||
| Portal | 0.167 | |||
| 0 | 21 (57) | 14 (67) | 7 (44) | |
| 1 | 11 (30) | 5 (24) | 6 (38) | |
| 2 | 5 (14) | 2 (10) | 3 (19) | |
| Lobular | 0.366 | |||
| 0 | 32 (87) | 19 (91) | 13 (81) | |
| 1 | 3 (8) | 2 (10) | 1 (6) | |
| 2 | 2 (5) | 0 (0) | 2 (13) | |
| Central | 0.252 | |||
| 0 | 36 (97) | 21 (100) | 15 (94) | |
| 1 | 0 (0) | 0 (0) | 0 (0) | |
| 2 | 1 (3) | 0 (0) | 1 (6) | |
| CD34 | ||||
| Portal | 0.976 | |||
| 0 | 38 (80) | 23 (79) | 15 (79) | |
| 1 | 9 (19) | 5 (17) | 4 (21) | |
| 2 | 1 (2) | 1 (3) | 0 (0) | |
| Central | 0.280 | |||
| 0 | 33 (69) | 22 (76) | 11 (58) | |
| 1 | 13 (27) | 5 (17) | 8 (42) | |
| 2 | 2 (4) | 2 (7) | 0 (0) | |
α-SMA – α-smooth muscle actin; PSGL-1 – P-selectin glycoprotein ligand-1.
*
p-value for the significance of the difference in the distribution of biomarker scores between patients without and with fibrosis calculated with Kruskal-Wallis test.